Aléxia Polo Siqueira

Ms. Aléxia Polo Siqueira


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KTKatiane Tostes
Katiane Tostes
ASAléxia Polo Siqueira
Aléxia Polo Siqueira
RRRui M. Reis
Rui M. Reis
LLLeticia Ferro Leal
Leticia Ferro Leal
LALidia Maria Rebolho Batista Arantes
Lidia Maria Rebolho Batista Arantes
Lung cancer has the highest mortality rate among all cancer types, resulting in over 1.8 million deaths annually. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) has revolutionized the treatment of non-small cell lung cancer (NSCLC). ICIs, predominantly monoclonal antibodies, modulate co-stimulatory and co-inhibitory signals crucial for maintaining immune tolerance. Despite significant therapeutic advancements in NSCLC, patients still face challenges such as disease progression, recurrence, and high mortality rates. Therefore, there is a need for predictive biomarkers that can guide lung cancer treatment strategies. Currently, programmed death-ligand 1 (PD-L1) expression is the only established biomarker for predicting ICI response. However, its accuracy and robustness are not consistently reliable. This review provides an overview of potential biomarkers currently under development or in the validation stage that hold promise in improving the classification of responders and non-responders to ICI therapy in the near future.

17 November 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
MBMariane Minussi Baptistella
Mariane Minussi Baptistella
ASAléxia Polo Siqueira
Aléxia Polo Siqueira
DMDâmaris Lizia Santos Magalhães
Dâmaris Lizia Santos Magalhães
BZBruno Zavan
Bruno Zavan
COCarolina Oliveira
Carolina Oliveira
Pollyanna Francielli de OliveiraPollyanna Francielli de Oliveira
Pollyanna Francielli de Oliveira
Colorectal cancer (CRC) therapy frequently relies on chemotherapeutic agents with high cytotoxicity, low selectivity, and suboptimal efficacy. Thus, the search for alternative therapeutic strategies for CRC continues. In the present work, the antitumor potential of a hybrid compound, which contains fragments derived from resveratrol and curcumin, was evaluated. These natural compounds are known by their antioxidant, chemopreventive, and chemotherapeutic properties. Different methodologic approaches were used to investigate cytotoxic, genotoxic, antiproliferative, and antioxidant effects of a hybrid compound, named PQM-162, on HCT-8 colorectal cancer cells. The results showed that PQM-162 displays radical scavenging capacity as demonstrated by DPPH assay. Furthermore, this substance reduced cell viability and inhibited cell cycle progression at G2/M in HCT-8 cells. Antiproliferative activity of PQM-162 was associated with its ability to modulate the expression of critical regulators of G2/M transition and mitosis progression such as PLK1, AURKB, and CDKN1A. Taken together, our data indicate that PQM-162 is a promising antitumor agent due to its disruption of the redox balance in cancer cells and its modulation of the expression of regulators of the cell cycle and mitotic apparatus.

1 September 2025 in Translational Lung Cancer Research
Verified
Journal Article
Open access
PDF file
KTKatiane Tostes
Katiane Tostes
TDTauana Christina Dias
Tauana Christina Dias
GRGabriela Karam Rebolho
Gabriela Karam Rebolho
ICIsabela Fernandes Rivelli Cardoso
Isabela Fernandes Rivelli Cardoso
GBGabriela Panini Batagelo
Gabriela Panini Batagelo
LALidia Maria Rebolho Batista Arantes
Lidia Maria Rebolho Batista Arantes
Background: Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) representing 85% of cases. Immune checkpoint inhibitors (ICIs) have improved NSCLC treatment, but many patients still have poor responses or severe side effects. Reliable biomarkers are needed to predict treatment outcomes and personalize therapy. Hematological markers from complete blood count (CBC) have gained attention as accessible, low-cost prognostic tools reflecting systemic inflammation and immune status. Most studies focus on baseline values, leaving the prognostic relevance of their dynamic changes during treatment underexplored. This highlights the importance of investigating longitudinal hematological profiles in immunotherapy settings. The aim of this study is to investigate whether longitudinal changes in CBC parameters can serve as prognostic biomarkers in NSCLC patients treated with ICI. Methods: This retrospective study included 141 patients with NSCLC treated with ICIs between 2018 and 2024 at Barretos Cancer Hospital, Brazil. Eligible patients were ≥18 years old, had a confirmed NSCLC diagnosis, and had documented advanced-stage disease. Clinical data, including demographics, Eastern Cooperative Oncology Group (ECOG) status, smoking history, tumor histology, programmed death ligand-1 (PD-L1) expression, CBC values, treatment regimen, and response assessments, were obtained from medical records. Hematological parameters were assessed at diagnosis, baseline, and after three cycles of ICI. These parameters were analyzed individually and through composite scores, including a novel Monocyte-Platelet-Hemoglobin-Hematocrit (MPHH) score. Response was evaluated by RECIST 1.1, and overall survival (OS) and progression-free survival (PFS) by Kaplan-Meier and Cox models. Results: The median age was 65 years, with adenocarcinoma representing the predominant histological subtype (57.1%). The majority of patients were diagnosed at stage IV (60.9%), and PD-L1 positivity was observed in 62.9% of cases. Overall, 70.5% of patients achieved a clinical response to immunotherapy. The MPHH score demonstrated significant prognostic value for both treatment response and survival outcomes. Non-responders exhibited higher baseline MPHH values (P=0.04). Lower baseline scores (≤400.3) were associated with improved OS (P=0.007) and PFS (P=0.01). Post-treatment assessments further supported its predictive role, as patients with MPHH ≤305.9 after three cycles of ICI therapy showed significantly longer overall (P=0.005) and PFS (P<0.001). Conclusions: These findings highlight the potential of CBC-derived scores, such as the MPHH, as valuable prognostic tools. CBC markers are particularly important in resource-limited settings where access to advanced molecular profiling is restricted. Integrating hematological profiles into clinical decision-making could facilitate more personalized treatment approaches and improve patient outcomes.

9 September 2023 in European Respiratory Journal
Verified
Conference Paper
Closed access
ASAléxia Polo Siqueira
Aléxia Polo Siqueira
MGMaria Fernanda Santiago Gonçalves
Maria Fernanda Santiago Gonçalves
ITIsabella Lemuqui Tegami
Isabella Lemuqui Tegami
KMKeila Cristina Miranda
Keila Cristina Miranda
ÍPÍcaro Alves Pinto
Ícaro Alves Pinto
LLLetícia Ferro Leal
Letícia Ferro Leal
Background: Recommendation of adjuvant chemotherapy(ACT) is based on tumor size and lymph node invasion for early-stage surgically resected non-small cell lung cancer(NSCLC) patients. Specific criteria lack to define who will be benefit from ACT. Aim: To evaluate the reproducibility of a 12-gene panel to predict ACT benefit and prognosis for early-stage NSCLC patients. Methods: Formalin-fixed paraffin-embedded(FFPE) samples from surgically resected patients(n=139) were retrospectively included. RNA-based expression of 12 genes was evaluated by NanoString (ATP8A1, AURKA, C1orf116, COL4A3, DOCK9, HOPX, HSD17B6, IFT57, MBIP, NKX2-1, RRM2 and TTC37). Patients were stratified as low-risk(ACT non-benefit) and a high-risk (ACT-benefit), and overall(OS) and event-free survival(EFS) were assessed. Results: The RNA-based panel present a 0.8% failure rate. This panel successfully stratified patients(n=138) as low- and high-risk regardless of ACT treatment. Low-risk patients presented an improvement of 15 months in both OS and EFS compared with high-risk(pOS<0.0001, pEFS<0.001). Median survival was not reached. Regarding the predictive performance, ACT-treated high-risk(n=50) patients had an improvement of 5 months of OS(x͂OS=22.6mos.) and EFS(x͂EPFS=19.7mos.) compared with untreated patients(x͂OS=17.5mos., x͂EPFS=14.7mos.). Low-risk patients(n=88) had similar outcomes for ACT-treated and ACT-untreated patients for both OS and EFS. Conclusion: The 12-gene expression panel successfully stratify low- and high-risk patients, and may be a promising predictive tool for clinical management of early-stage NSCLC patients.

12 August 2026 in Journal of Applied Toxicology
Verified
Journal Article
Open access
LPLeticia Helena Parreira
Leticia Helena Parreira
EMEvelyn Pinheiro de Mendonça
Evelyn Pinheiro de Mendonça
ASAléxia Polo Siqueira
Aléxia Polo Siqueira
CCCleydson Finotti Cordeiro
Cleydson Finotti Cordeiro
ESElkin José Torres Sierra
Elkin José Torres Sierra
Pollyanna Francielli de OliveiraPollyanna Francielli de Oliveira
Pollyanna Francielli de Oliveira
Coumarins are phenolic compounds widely recognized for their diverse pharmacological activities and have attracted increasing attention as potential chemopreventive agents. In the present study, four known 3‐benzoylcoumarin derivatives [( 1 ), ( 2 ), ( 3 ), and ( 4 )] were evaluated for their cytotoxic, mutagenic, and antigenotoxic effects in Chinese hamster lung fibroblasts (V79 cells). Cytotoxicity was initially assessed using the MTT assay to establish sub‐cytotoxic concentrations for subsequent analyses. Genotoxicity and chemopreventive activity were investigated using the cytokinesis‐block micronucleus (CBMN) assay following DNA damage induced by doxorubicin (DXR) or methyl methanesulfonate (MMS). All compounds exhibited concentration‐dependent cytotoxicity, with ( 2 ) showing the greatest potency. In the CBMN assay, none of the compounds significantly altered the nuclear division index (NDI), indicating the absence of cytostatic effects. However, at higher concentrations, the derivatives increased micronucleus (MN) frequency, suggesting the induction of chromosomal damage. In the antigenotoxicity assay, differential protective effects were observed depending on the mutagen used. Cotreatment with DXR demonstrated that ( 1 ) significantly reduced MN frequency at the highest tested concentration, whereas ( 3 ) and ( 4 ) significantly decreased DXR‐induced chromosomal damage. When MMS was used as the mutagenic agent, ( 2 ) significantly reduced MN formation at lower concentrations. Taken together, these findings support a Janus‐like behavior of 3‐benzoylcoumarins and indicate dose‐dependent genotoxic and antigenotoxic properties and highlight their potential as modulators of DNA damage induced by different mutagenic mechanisms. Overall, these findings highlight the concentration‐dependent dual biological effects of 3‐benzoylcoumarins and support further investigations into their potential as chemopreventive agents.